Autobahn: fine-tuning thyroid agonism to remyelinate axons

Arch-incubated remyelination play Autobahn launches with $76M series B

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next year, has a stronger genetic rationale than competing programs.

Arch Venture Partners incubated the biotech and co-led the untranched round with Cowen Healthcare Investments.

Arch’s Keith Lenden is president, COO and co-founder of Autobahn Therapeutics.

Also participating in the round are BVF Partners, Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32, Samsara BioCapital

Read the full 911 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE